Afuco™ Anti-Human ENG ADCC Therapeutic Antibody (TRC105), ADCC Enhanced
Anti-ENG ADCC Enhanced Antibody (TRC105) is an ADCC enhanced antibody produced by our Afuco™ platform. TRC105 is a novel, clinical stage antibody to endoglin, which is a protein that is overexpressed on endothelial cells and is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials for the treatment of multiple solid tumor types, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, hepatocellular carcinoma and colorectal cancer, in combination with VEGF inhibitors.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-220CL |
| Pricing | Inquiry |
| Host | Chimeric (human/mouse) |
| Target | ENG |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C |